ProQR Therapeutics (NASDAQ:PRQR – Get Rating) – Cantor Fitzgerald lifted their FY2022 EPS estimates for ProQR Therapeutics in a research note issued to investors on Monday, August 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the biopharmaceutical company will post earnings per share of ($0.77) for the year, up from their prior forecast of ($0.84). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.83) per share. Cantor Fitzgerald also issued estimates for ProQR Therapeutics' FY2023 earnings at ($0.62) EPS.
Get
ProQR Therapeutics alerts:
A number of other brokerages have also recently weighed in on PRQR. HC Wainwright dropped their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a research report on Monday, May 9th. Raymond James raised shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price objective for the company in a research note on Friday, August 12th. Chardan Capital lowered shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $5.00.
ProQR Therapeutics Price Performance
Shares of PRQR opened at $0.85 on Wednesday. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $9.09. The stock has a market cap of $60.60 million, a PE ratio of -0.85 and a beta of 0.80. The firm has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $1.14. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of ProQR Therapeutics during the 2nd quarter worth approximately $48,000. ProShare Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $80,000. Monaco Asset Management SAM purchased a new stake in shares of ProQR Therapeutics during the 1st quarter worth approximately $82,000. Coastal Bridge Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $85,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of ProQR Therapeutics by 22.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 2,352 shares during the last quarter.
ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
See Also
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
